Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elusys Therapeutics and Lonza have extended their manufacturing agreement to scale-up the commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax.
Subscribe to our email newsletter
As per the agreement, Lonza is expected to support process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the US.
Lonza was optimised for the full scale production and manufacturing process for Anthim in 2009, under a separate agreement signed between the two entities.
Additionally, in 2009, the Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services, had offered a $143m contract to complete the final development, commercial manufacturing and licensure of Anthim.
James Porter, vice president of development and manufacturing at Elusys, said: “Elusys is pleased to extend its relationship with Lonza for the commercial production of Anthim, an anti-toxin that has been highly effective in treating anthrax infected animals.
“We believe that partnering with Lonza provides Elusys the manufacturing experience and large-scale capacity needed to ensure commercial quantities of Anthim long-term.”
Stephan Kutzer, head of custom manufacturing at Lonza, said: “Working with the team at Elusys on such a novel new antibody therapy has been very rewarding. We are excited about continuing our successful relationship and look forward to supporting Elusys in the launch and long-term commercial supply of Anthim.”